CIK 0001658247
CRNX Crinetics Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 40 d ago. Close $84.95 on Aug 31, 2026, 0% from the 52-week low and 0% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at Crinetics Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Stephen F. Betz Chief Scientific Officer sell | $197k 5,770 shares | -5% | - | |
| 39Weak | Richard Scott Struthers President & CEO sell | $593k 17,338 shares | -5% | - | |
| 28Weak | Jeff E. Knight Chief Operating Officer sell | $245k 7,162 shares | -8% | - | |
| 19Weak | Dana Pizzuti Chief Med and Dev Officer sell | $86k 2,515 shares | -3% | - | |
| 0Weak | Dana Pizzuti Chief Med and Dev Officer sell | $195k 5,000 shares | -14% | - | |
| 12Weak | Dana Pizzuti Chief Med and Dev Officer sell | $781k 15,000 shares | -34% | - | |
| 32Weak | Richard Scott Struthers President & CEO sell | $576k 10,000 shares | -9% | - | |
| 13Weak | Jeff E. Knight Chief Operating Officer sell | $28k 501 shares | -1% | - |
Congressional trades
5 trades in CRNX disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr. House · D-CA | Sale | CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $15k to $50k | Jul 30 / Sep 4 36 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Mar 3 / Apr 7 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 17, 2025 / May 6, 2025 19 days after the trade | Clerk |
Josh Gottheimer House · D-NJ | Sale | CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Mar 19, 2025 / Apr 10, 2025 22 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Jan 29, 2025 / Feb 11, 2025 13 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Common Stock | -6,400 | $85.00 | $544k | 5,925 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Common Stock | -116,146 | $85.00 | $9.9M | 5,925 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Common Stock | -13,300 | $85.00 | $1.1M | 5,925 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stock | -248,043 | $85.00 | $21M | 176,663 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Common Stock | -58,286 | $85.00 | $5.0M | 79,650 | 40 d ago |
| Sep 1, 2026 | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Common Stock | -1,669 | $85.00 | $142k | 34,000 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 40 d ago |
| Sep 1, 2026 | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Common Stock | -7,956 | $85.00 | $676k | 71,471 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Common Stock | -22,836 | $85.00 | $1.9M | 5,925 | 40 d ago |
| Sep 1, 2026 | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Common Stock | -34,000 | $85.00 | $2.9M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Common Stock | -71,471 | $85.00 | $6.1M | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Common Stock | -79,650 | $85.00 | $6.8M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Spouse | -1,000 | $85.00 | $85k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 1 | -136,805 | $85.00 | $12M | 0 | 40 d ago |
| Sep 1, 2026 | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -97,500 | $44.41 | $4.3M | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $56.69 | $2.0M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.76 | $772k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,514 | $83.09 | $7.5M | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.76 | $772k | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $68.92 | $1.7M | 0 | 40 d ago |
| Sep 1, 2026 | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | $51.25 | $4.1M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $60.85 | $1.5M | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $65.70 | $2.3M | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,092 | $83.09 | $174k | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.77 | $772k | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.77 | $772k | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,750 | $66.71 | $584k | 0 | 40 d ago |
| Sep 1, 2026 | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,000 | $41.21 | $2.3M | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.77 | $772k | 0 | 40 d ago |
| Sep 1, 2026 | Tobin Schilke Chief Financial & Infra. Ofcr. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | $41.21 | $2.1M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 2 | -106,000 | $85.00 | $9.0M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -74,540 | $75.72 | $5.6M | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,375 | $66.71 | $292k | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 3 | -110,000 | $85.00 | $9.3M | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,250 | $59.81 | $3.4M | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $66.71 | $1.2M | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $66.71 | $1.2M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $66.71 | $1.2M | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 4 | -100,000 | $85.00 | $8.5M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -60,000 | $62.39 | $3.7M | 0 | 40 d ago |
| Sep 1, 2026 | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -85,000 | $69.71 | $5.9M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 5 | -111,100 | $85.00 | $9.4M | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | $61.81 | $927k | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 40 d ago |
| Sep 1, 2026 | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 6 | -111,100 | $85.00 | $9.4M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -77,000 | $64.98 | $5.0M | 0 | 40 d ago |
| Sep 1, 2026 | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 7 | -111,100 | $85.00 | $9.4M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Family Trust 8 | -111,100 | $85.00 | $9.4M | 0 | 40 d ago |
| Sep 1, 2026 | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,000 | $65.36 | $7.2M | 0 | 40 d ago |
| Sep 1, 2026 | Wendell Wierenga director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stockindirect: By Charitable Trust | -80,000 | $85.00 | $6.8M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -87,000 | $41.49 | $3.6M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Common Stock | -176,663 | $85.00 | $15M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -65,000 | $48.14 | $3.1M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -172,281 | $59.81 | $10M | 0 | 40 d ago |
| Sep 1, 2026 | Stephen F. Betz Chief Scientific Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,000 | $41.21 | $1.9M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -195,578 | $62.39 | $12M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -259,058 | $69.71 | $18M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -244,205 | $64.98 | $16M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -287,700 | $65.36 | $19M | 0 | 40 d ago |
| Sep 1, 2026 | Richard Scott Struthers President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -240,000 | $41.49 | $10.0M | 0 | 40 d ago |
Insiders
Everyone who has filed a Form 4 here.
- Camille L Bedrosianofficer, director
- Stephen F. BetzChief Scientific Officer
- Caren Deardorfdirector
- Matthew K Fustdirector
- Isabel KalofonosChief Commercial Officer
- Jeff E. KnightChief Operating Officer
- Weston Nicholsowner, director
- Stephanie Okeydirector
- Dana PizzutiChief Med and Dev Officer
- Tobin SchilkeChief Financial & Infra. Ofcr.
- Richard Scott StruthersPresident & CEO
- Coelho Rogerio Vivaldidirector
- Wendell Wierengadirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.